Article
Preliminary evidence shows ranibizumab benefit in DME
Las Vegas-A pilot study of ranibizumab (Lucentis, Genentech), a vascular endothelial growth factor (VEGF) antagonist, showed that the drug has a biological effect in diabetic macular edema (DME), reported Peter Campochiaro, MD, who spoke at the American Academy of Ophthalmology annual meeting.
Related Videos
Related Content
